This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
trigram | frequency |
---|---|
stem cell transplantation | 1644 |
in patients with | 1283 |
hematopoietic stem cell | 953 |
as well as | 846 |
the use of | 683 |
cd t cells | 629 |
the presence of | 623 |
of patients with | 551 |
of the patients | 547 |
conflict of interest | 522 |
disclosure of conflict | 479 |
of conflict of | 479 |
the incidence of | 463 |
the development of | 431 |
allogeneic stem cell | 418 |
the treatment of | 408 |
is associated with | 398 |
allogeneic hematopoietic stem | 396 |
with a median | 389 |
the time of | 380 |
the role of | 372 |
the risk of | 369 |
for patients with | 360 |
a total of | 359 |
the number of | 359 |
the most common | 356 |
in order to | 354 |
at the time | 347 |
stem cell transplant | 321 |
a median of | 318 |
in this study | 317 |
nothing to declare | 316 |
cd and cd | 306 |
there was no | 303 |
was associated with | 299 |
associated with a | 298 |
according to the | 292 |
a median follow | 288 |
the absence of | 283 |
of this study | 274 |
cumulative incidence of | 272 |
study was to | 267 |
one of the | 263 |
risk factors for | 263 |
due to the | 263 |
the majority of | 257 |
morbidity and mortality | 257 |
the impact of | 254 |
bone marrow transplantation | 249 |
the aim of | 245 |
was observed in | 243 |
at a median | 237 |
the diagnosis of | 235 |
peripheral blood stem | 229 |
this study was | 224 |
patients who received | 221 |
the effect of | 220 |
lung transplant recipients | 218 |
versus host disease | 217 |
in the first | 216 |
the outcome of | 214 |
graft versus host | 214 |
were treated with | 213 |
in the absence | 212 |
as compared to | 211 |
in addition to | 210 |
median age of | 208 |
in terms of | 208 |
median age was | 203 |
the median age | 202 |
in patients who | 201 |
to evaluate the | 201 |
for the treatment | 200 |
by flow cytometry | 199 |
in the presence | 196 |
has not been | 195 |
patients with a | 193 |
median time to | 192 |
hematopoietic cell transplantation | 191 |
the expression of | 189 |
years of age | 188 |
based on the | 188 |
found to be | 185 |
in all patients | 185 |
there were no | 184 |
autologous stem cell | 183 |
cd t cell | 182 |
aim of this | 182 |
been shown to | 180 |
cells in the | 178 |
acute myeloid leukemia | 176 |
there was a | 174 |
the median time | 171 |
is the most | 171 |
compared to the | 169 |
in combination with | 169 |
mg kg day | 168 |
stem cell source | 167 |
t cells and | 166 |
in of patients | 165 |
has been reported | 165 |
organ transplant recipients | 165 |
t cells in | 164 |
all patients received | 162 |
to determine the | 161 |
in the treatment | 161 |
of the disease | 159 |
solid organ transplant | 159 |
median follow up | 158 |
in response to | 156 |
median age at | 156 |
patients who underwent | 156 |
of these patients | 154 |
we found that | 153 |
the conditioning regimen | 153 |
reduced intensity conditioning | 152 |
was used to | 150 |
and in the | 150 |
with or without | 150 |
associated with the | 150 |
has been shown | 149 |
after allogeneic hematopoietic | 149 |
was found to | 149 |
and chronic gvhd | 148 |
should be considered | 148 |
the setting of | 147 |
acute and chronic | 146 |
there is no | 146 |
in the setting | 146 |
increased risk of | 145 |
the frequency of | 145 |
and cd t | 145 |
were associated with | 144 |
been associated with | 143 |
patients in the | 143 |
to assess the | 143 |
it has been | 143 |
the united states | 143 |
are associated with | 142 |
age was years | 142 |
all patients were | 142 |
t cells were | 141 |
there is a | 141 |
human immunodeficiency virus | 140 |
up of months | 140 |
role in the | 140 |
during the first | 139 |
risk factor for | 139 |
a number of | 138 |
the present study | 137 |
of patients who | 137 |
of acute gvhd | 136 |
after a median | 136 |
median time of | 136 |
in both groups | 136 |
in children with | 135 |
blood stem cells | 135 |
quality of life | 134 |
were included in | 134 |
patients treated with | 132 |
in solid organ | 132 |
median number of | 131 |
renal transplant recipients | 131 |
herpes simplex virus | 130 |
of cd cells | 130 |
be associated with | 129 |
the most frequent | 129 |
have been reported | 129 |
the cumulative incidence | 128 |
patients with acute | 128 |
respiratory syncytial virus | 128 |
of cmv infection | 127 |
the management of | 127 |
the efficacy of | 127 |
shown to be | 126 |
a variety of | 126 |
bone marrow transplant | 126 |
the results of | 125 |
total of patients | 124 |
the first year | 124 |
blood stem cell | 124 |
in lung transplant | 123 |
in these patients | 123 |
after allogeneic stem | 123 |
to be a | 122 |
in the united | 121 |
the patients with | 120 |
of the immune | 120 |
a patient with | 120 |
haematopoietic stem cell | 119 |
the immune system | 119 |
no significant difference | 119 |
polymerase chain reaction | 118 |
cell transplant recipients | 118 |
analysis of the | 118 |
a history of | 117 |
months of age | 117 |
the rate of | 117 |
for the first | 116 |
as part of | 116 |
data suggest that | 115 |
intensive care unit | 115 |
of t cells | 115 |
acute lymphoblastic leukemia | 115 |
within the first | 114 |
included in the | 114 |
before and after | 114 |
is a rare | 113 |
as a result | 113 |
the patient was | 113 |
specific t cells | 112 |
at time of | 112 |
in peripheral blood | 112 |
well as the | 112 |
median of days | 111 |
the onset of | 111 |
of the study | 111 |
was defined as | 111 |
of cd t | 111 |
patients who had | 110 |
none of the | 110 |
associated with increased | 110 |
follow up of | 110 |
involved in the | 110 |
to investigate the | 109 |
and overall survival | 109 |
the age of | 108 |
the risk for | 108 |
the course of | 108 |
was performed in | 108 |
cell transplantation in | 107 |
the importance of | 107 |
the occurrence of | 107 |
cohort of patients | 107 |
specific cd t | 107 |
seems to be | 107 |
in contrast to | 106 |
the pathogenesis of | 106 |
was detected in | 105 |
allogeneic hematopoietic cell | 105 |
significant difference in | 104 |
in of the | 104 |
for treatment of | 104 |
in a patient | 104 |
in the early | 104 |
solid organ transplantation | 104 |
total body irradiation | 104 |
at least one | 103 |
infection in the | 103 |
of patients were | 103 |
was significantly higher | 102 |
year overall survival | 102 |
the lack of | 102 |
and treatment of | 102 |
in renal transplant | 102 |
the need for | 101 |
number of patients | 101 |
a median time | 100 |
in the study | 100 |
a median age | 100 |
of t cell | 100 |
was used in | 100 |
can be used | 100 |
with respect to | 100 |
conditioning regimen was | 99 |
is one of | 99 |
majority of patients | 99 |
umbilical cord blood | 99 |
in multivariate analysis | 99 |
an increase in | 99 |
age of years | 99 |
associated with an | 98 |
patients with severe | 98 |
the first months | 98 |
the induction of | 97 |
to reduce the | 97 |
patients with high | 97 |
may be a | 97 |
in our center | 97 |
in immunocompromised patients | 96 |
the end of | 96 |
a result of | 96 |
incidence of relapse | 96 |
cause of death | 96 |
number of cd | 95 |
because of the | 94 |
the patients who | 94 |
patients who were | 94 |
was seen in | 94 |
when compared to | 94 |
out of patients | 94 |
a combination of | 94 |
is characterized by | 94 |
the effects of | 93 |
in case of | 93 |
central nervous system | 92 |
part of the | 92 |
a cohort of | 92 |
used in the | 92 |
been reported in | 92 |
between january and | 92 |
patients received a | 92 |
regulatory t cells | 92 |
group of patients | 92 |
an important role | 92 |
the level of | 92 |
results suggest that | 91 |
been reported to | 91 |
patients were treated | 91 |
all patients had | 91 |
significantly higher in | 91 |
and bone marrow | 91 |
matched unrelated donor | 91 |
the addition of | 90 |
were used to | 90 |
gd t cells | 90 |
the prevalence of | 90 |
the context of | 90 |
related to the | 90 |
a role in | 89 |
iv acute gvhd | 89 |
the case of | 89 |
appears to be | 89 |
are needed to | 89 |
lower respiratory tract | 88 |
the activation of | 88 |
in the present | 88 |
were able to | 88 |
the combination of | 88 |
of chronic gvhd | 88 |
of stem cells | 88 |
the two groups | 87 |
the first days | 87 |
this is the | 87 |
increase in the | 87 |
we investigated the | 87 |
patients had a | 87 |
after hematopoietic stem | 87 |
significantly associated with | 87 |
the most important | 87 |
in the context | 86 |
safety and efficacy | 86 |
in complete remission | 86 |
no difference in | 86 |
the production of | 85 |
high levels of | 85 |
in recipients of | 85 |
on the other | 85 |
were found to | 85 |
has also been | 85 |
is the first | 85 |
depending on the | 85 |
chronic gvhd was | 85 |
hematopoietic stem cells | 84 |
we show that | 84 |
the severity of | 84 |
in vitro and | 84 |
we report the | 84 |
incidence of acute | 84 |
and management of | 83 |
were observed in | 83 |
the duration of | 83 |
between the two | 83 |
expression of the | 82 |
t cell receptor | 82 |
not associated with | 82 |
with a high | 82 |
the patients were | 82 |
in association with | 82 |
acute gvhd was | 82 |
the median follow | 82 |
resulted in a | 82 |
for the development | 82 |
the control group | 81 |
patients with aml | 81 |
used as a | 81 |
hepatitis c virus | 81 |
who did not | 81 |
p disclosure of | 80 |
t cells from | 80 |
in all cases | 79 |
the type of | 79 |
an increased risk | 79 |
was treated with | 79 |
of the most | 79 |
we performed a | 79 |
study is to | 78 |
neutrophil and platelet | 78 |
and nk cells | 78 |
found to have | 78 |
at our institution | 78 |
in transplant recipients | 78 |
of cmv reactivation | 78 |
most of the | 77 |
a dose of | 77 |
in comparison to | 77 |
the other hand | 77 |
we aimed to | 77 |
and efficacy of | 77 |
the prevention of | 77 |
with and without | 76 |
has been associated | 76 |
t cell activation | 76 |
important role in | 76 |
need to be | 76 |
is an important | 76 |
allogeneic bone marrow | 76 |
the proportion of | 76 |
to analyze the | 76 |
was no significant | 75 |
full donor chimerism | 75 |
of hematopoietic stem | 75 |
can lead to | 75 |
have shown that | 75 |
the bone marrow | 75 |
due to a | 75 |
at our center | 75 |
occurred in patients | 75 |
the first time | 75 |
in breast milk | 75 |
and mortality in | 75 |
higher in the | 74 |
shown in table | 74 |
and safety of | 74 |
are shown in | 74 |
compared to those | 74 |
of the patient | 74 |
of cd and | 74 |
in patients undergoing | 74 |
after lung transplantation | 74 |
the t cell | 73 |
died due to | 73 |
in a single | 73 |
in patients receiving | 73 |
was used as | 73 |
has been used | 73 |
t cells with | 73 |
of cd cd | 72 |
was no difference | 72 |
we retrospectively analyzed | 72 |
in the literature | 72 |
more likely to | 72 |
west nile virus | 72 |
median time from | 72 |
t cell responses | 72 |
analysis was performed | 72 |
high risk of | 72 |
have been described | 72 |
we analyzed the | 72 |
blood and marrow | 72 |
dose of mg | 72 |
have not been | 72 |
from patients with | 72 |
overall survival was | 72 |
no significant differences | 72 |
memory t cells | 72 |
in pts with | 71 |
patients are alive | 71 |
the ability of | 71 |
was diagnosed with | 71 |
is important to | 71 |
the identification of | 71 |
observed in patients | 71 |
cell transplantation for | 71 |
t and b | 71 |
patients were transplanted | 71 |
in the group | 71 |
median duration of | 71 |
the percentage of | 71 |
was used for | 71 |
in the pathogenesis | 70 |
this is a | 70 |
at years was | 70 |
was assessed by | 70 |
was significantly lower | 70 |
to identify the | 70 |
play a role | 70 |
transplant related mortality | 70 |
a diagnosis of | 70 |
was to evaluate | 70 |
and mycophenolate mofetil | 70 |
we conclude that | 70 |
be considered in | 70 |
be used to | 69 |
for the diagnosis | 69 |
a risk factor | 69 |
of morbidity and | 69 |
disclosure of interest | 69 |
in pediatric patients | 69 |
here we report | 69 |
months after transplantation | 69 |
in comparison with | 69 |
there are no | 69 |
for at least | 69 |
risk of relapse | 69 |
to have a | 69 |
in bone marrow | 68 |
the immune response | 68 |
difference in the | 68 |
it is not | 68 |
to declare background | 68 |
adult patients with | 68 |
the fact that | 68 |
heart transplant recipients | 68 |
at the same | 68 |
compared to patients | 68 |
and platelet engraftment | 67 |
we hypothesized that | 67 |
the study was | 67 |
minimal residual disease | 67 |
of the virus | 67 |
cd cd cd | 67 |
was performed by | 67 |
no evidence of | 67 |
all patients with | 67 |
causes of death | 67 |
the detection of | 67 |
severe acute respiratory | 67 |
the overall survival | 66 |
in our study | 66 |
proportion of patients | 66 |
myeloablative conditioning regimen | 66 |
observed in the | 66 |
acute gvhd grade | 66 |
the general population | 66 |
were diagnosed with | 66 |
could not be | 66 |
of allogeneic hematopoietic | 66 |
patients with chronic | 66 |
time to neutrophil | 65 |
acute renal failure | 65 |
from diagnosis to | 65 |
after bone marrow | 65 |
at a dose | 65 |
donor and recipient | 65 |
cmv infection in | 65 |
patients were included | 65 |
major cause of | 65 |
patients with cmv | 65 |
in cases of | 65 |
a retrospective analysis | 65 |
whole exome sequencing | 65 |
in the case | 65 |
at high risk | 65 |
infections in the | 65 |
to be the | 65 |
the introduction of | 65 |
was found in | 65 |
the median number | 65 |
of peripheral blood | 64 |
t cell depletion | 64 |
is a major | 64 |
risk of developing | 64 |
the outcomes of | 64 |
suggest that the | 64 |
contribute to the | 64 |
outcome of patients | 64 |
in patients and | 64 |
in one patient | 64 |
in children and | 64 |
was diagnosed in | 64 |
of nk cells | 64 |
between the groups | 64 |
higher incidence of | 64 |
peripheral blood mononuclear | 64 |
t cell proliferation | 64 |
in the majority | 64 |
kidney transplant recipients | 64 |
and in vivo | 64 |
in the last | 63 |
bone marrow failure | 63 |
may lead to | 63 |
a single center | 63 |
the basis of | 63 |
compared with the | 63 |
to study the | 63 |
for the prevention | 63 |
in der regel | 63 |
found in the | 63 |
prophylaxis consisted of | 63 |
is the only | 63 |
after the first | 63 |
we observed a | 63 |
present in the | 63 |
blood mononuclear cells | 63 |
a retrospective study | 63 |
in our series | 63 |
with an increased | 62 |
it is important | 62 |
of patients in | 62 |
was performed using | 62 |
was performed with | 62 |
in the control | 62 |
extensive chronic gvhd | 62 |
at the end | 62 |
incidence of cmv | 62 |
to be associated | 62 |
the purpose of | 62 |
to compare the | 62 |
this study we | 62 |
the fi rst | 61 |
patients who are | 61 |
did not have | 61 |
the same time | 61 |
to the development | 61 |
was higher in | 61 |
as gvhd prophylaxis | 61 |
all of them | 61 |
in this setting | 61 |
for all patients | 61 |
this study is | 61 |
patients with primary | 61 |
retrospective analysis of | 61 |
were detected in | 61 |
have been shown | 61 |
in this patient | 61 |
the regulation of | 60 |
of the first | 60 |
the probability of | 60 |
included in this | 60 |
patients and methods | 60 |
age at transplant | 60 |
a and b | 60 |
the administration of | 60 |
associated with higher | 60 |
up to of | 60 |
factors associated with | 60 |
of children with | 60 |
was determined by | 60 |
to patients with | 60 |
the generation of | 60 |
disease status at | 60 |
higher risk of | 60 |
marrow transplant recipients | 60 |
expressed breast milk | 60 |
of cmv disease | 60 |
mutations in the | 60 |
cord blood transplantation | 60 |
and patients with | 60 |
high rate of | 59 |
cause of morbidity | 59 |
in our cohort | 59 |
were found in | 59 |
hepatitis b virus | 59 |
vitro and in | 59 |
donor t cells | 59 |
can also be | 59 |
acute respiratory syndrome | 59 |
b cells and | 59 |
be considered as | 59 |
severe combined immunodeficiency | 59 |
with high risk | 59 |
did not differ | 59 |
are the most | 59 |
and may be | 59 |
has been described | 59 |
the only curative | 59 |
the ability to | 58 |
infection of the | 58 |
aim of the | 58 |
liver transplant recipients | 58 |
the degree of | 58 |
this retrospective study | 58 |
may contribute to | 58 |
did not receive | 58 |
on the basis | 58 |
such as the | 58 |
changes in the | 58 |
of the liver | 58 |
samples were collected | 58 |
the possibility of | 58 |
with multiple myeloma | 58 |
be due to | 58 |
transplant recipients with | 58 |
were performed in | 58 |
at risk of | 58 |
a significant increase | 58 |
was the most | 58 |
with a history | 58 |
is based on | 58 |
the safety and | 58 |
was achieved in | 58 |
in the development | 57 |
patients with hiv | 57 |
were used as | 57 |
the influence of | 57 |
we did not | 57 |
our data suggest | 57 |
differences in the | 57 |
of patients had | 57 |
cd cell count | 57 |
a review of | 57 |
acute or chronic | 57 |
was present in | 57 |
resulting in a | 57 |
studies are needed | 57 |
of bone marrow | 56 |
bone marrow and | 56 |
a case of | 56 |
the peripheral blood | 56 |
with regard to | 56 |
the quality of | 56 |
at day and | 56 |
expression of cd | 56 |
we evaluated the | 56 |
age of the | 56 |
safe and effective | 55 |
and t cell | 55 |
results of a | 55 |
not statistically significant | 55 |
matched sibling donor | 55 |
autologous hematopoietic stem | 55 |
end of the | 55 |
but not in | 55 |
significantly lower in | 55 |
to determine whether | 55 |
to our knowledge | 55 |
the objective of | 55 |
mhc class i | 55 |
increased risk for | 55 |
activation of the | 55 |
results of the | 55 |
significant differences in | 55 |
data indicate that | 55 |
in the patients | 55 |
patients were in | 55 |
chronic granulomatous disease | 54 |
data on the | 54 |
reported to be | 54 |
the cause of | 54 |
invasive fungal infections | 54 |
mg kg kg | 54 |
and severity of | 54 |
little is known | 54 |
we observed that | 54 |
source of stem | 54 |
we conducted a | 54 |
or chronic gvhd | 54 |
review of the | 54 |
matched related donor | 54 |
is a common | 54 |
more than of | 54 |
the era of | 54 |
viral infections in | 54 |
median age years | 54 |
common cause of | 54 |
who received a | 54 |
cell source was | 54 |
after stem cell | 54 |
at last follow | 54 |
to declare p | 53 |
in patients after | 53 |
for prevention of | 53 |
the stem cell | 53 |
pneumocystis carinii pneumonia | 53 |
after renal transplantation | 53 |
showed that the | 53 |
in a cohort | 53 |
a prospective study | 53 |
likely to be | 53 |
at the age | 53 |
among patients with | 53 |
pediatric patients with | 53 |
of acute and | 53 |
we found a | 53 |
acute graft versus | 52 |
in the era | 52 |
virus infection in | 52 |
that can be | 52 |
of the cases | 52 |
some of the | 52 |
respiratory tract infections | 52 |
the association of | 52 |
is caused by | 52 |
we report a | 52 |
show that the | 52 |
fludarabine mg m | 52 |
more than one | 52 |
to that of | 52 |
may also be | 52 |
further studies are | 52 |
cd cells were | 52 |
haploidentical stem cell | 52 |
efficacy and safety | 52 |
the amount of | 52 |
the day of | 52 |
one patient with | 52 |
were used in | 52 |
of b cells | 52 |
respiratory distress syndrome | 52 |
t cells was | 52 |
the analysis of | 51 |
more common in | 51 |
after allogeneic hsct | 51 |
have been identified | 51 |
high incidence of | 51 |
in the patient | 51 |
in hiv patients | 51 |
patients with relapsed | 51 |
with hiv infection | 51 |
for patients who | 51 |
and can be | 51 |
option for patients | 51 |
in recent years | 51 |
the source of | 51 |
be used as | 51 |
any of the | 51 |
was carried out | 51 |
only one patient | 51 |
with a higher | 50 |
of patients and | 50 |
matched unrelated donors | 50 |
patients with aids | 50 |
of our study | 50 |
at months of | 50 |
and b cells | 50 |
of all patients | 50 |
in hematopoietic stem | 50 |
and stem cell | 50 |
common variable immunodeficiency | 50 |
were used for | 50 |
the spectrum of | 50 |
cd cells kg | 50 |
was started on | 50 |
to be effective | 50 |
and marrow transplantation | 50 |
of stem cell | 50 |
and cd cells | 50 |
in this group | 50 |
were collected from | 49 |
in a large | 49 |
high risk patients | 49 |
of the two | 49 |
patients with hematological | 49 |
the incidence and | 49 |
objective of this | 49 |
known to be | 49 |
from the same | 49 |
in this population | 49 |
significant increase in | 49 |
in out of | 49 |
critically ill patients | 49 |
in univariate analysis | 49 |
in t cell | 49 |
cell transplantation is | 49 |
and one patient | 49 |
progression free survival | 49 |
of the cd | 49 |
compared to healthy | 49 |
up was months | 49 |
prior to hsct | 49 |
patients suffering from | 49 |
the patient is | 49 |
of infectious complications | 49 |
each of the | 49 |
t cells are | 48 |
thought to be | 48 |
the function of | 48 |
play an important | 48 |
one patient died | 48 |
in which the | 48 |
in the course | 48 |
memory b cells | 48 |
acute gvhd and | 48 |
antigen presenting cells | 48 |
studies have shown | 48 |
is an effective | 48 |
risk of infection | 48 |
all the patients | 48 |
we demonstrate that | 48 |
was able to | 48 |
on day and | 48 |
a reduction in | 48 |
clinical trial registry | 48 |
and the median | 48 |
cd cell dose | 48 |
with acute leukemia | 48 |
cytomegalovirus infection in | 48 |
at years of | 48 |
one or more | 48 |
on day after | 48 |
and outcome of | 48 |
os and pfs | 48 |
a significantly higher | 48 |
members of the | 48 |
was performed on | 47 |
tumor necrosis factor | 47 |
and peripheral blood | 47 |
standard of care | 47 |
gvhd prophylaxis was | 47 |
time of transplant | 47 |
depends on the | 47 |
c bl mice | 47 |
levels of il | 47 |
in the blood | 47 |
summarized in table | 47 |
upper respiratory tract | 47 |
be involved in | 47 |
were transplanted in | 47 |
at risk for | 47 |
when compared with | 47 |
has been demonstrated | 47 |
patients have been | 47 |
followed by a | 47 |
patients with advanced | 47 |
as compared with | 47 |
a group of | 47 |
has to be | 47 |
have also been | 47 |
the gastrointestinal tract | 47 |
a decrease in | 46 |
seen in the | 46 |
a trend towards | 46 |
in the immunocompromised | 46 |
at transplant was | 46 |
a period of | 46 |
from peripheral blood | 46 |
on days and | 46 |
mg m day | 46 |
in of cases | 46 |
one patient had | 46 |
gvhd prophylaxis consisted | 46 |
we have previously | 46 |
in the same | 46 |
and the use | 46 |
an unrelated donor | 46 |
half of the | 46 |
not significantly different | 46 |
the patient with | 46 |
status of the | 46 |
patients with multiple | 46 |
in adult patients | 46 |
detected in the | 46 |
is known about | 46 |
t cells to | 46 |
was confirmed by | 46 |
are alive and | 46 |
clinical and laboratory | 46 |
follow up was | 46 |
in those with | 45 |
in more than | 45 |
from an hla | 45 |
after liver transplantation | 45 |
and duration of | 45 |
the primary endpoint | 45 |
patients with agvhd | 45 |
prior to the | 45 |
year os was | 45 |
neutrophil engraftment was | 45 |
the first month | 45 |
balb c mice | 45 |
of the conditioning | 45 |
bronchiolitis obliterans syndrome | 45 |
t cell response | 45 |
addition to the | 45 |
in some cases | 45 |
evaluation of the | 45 |
from january to | 45 |
fungal infections in | 45 |
is known to | 45 |
to improve the | 45 |
transplantation in patients | 45 |
have been associated | 45 |
effect on the | 45 |
infections in patients | 45 |
with the same | 45 |
months after hsct | 45 |
flow cytometry and | 45 |
of viral infections | 45 |
in the diagnosis | 45 |
the remaining patients | 45 |
impact on the | 45 |
reduction in the | 45 |
are summarized in | 45 |
been described in | 45 |
allogeneic haematopoietic stem | 44 |
were obtained from | 44 |
understanding of the | 44 |
highly active antiretroviral | 44 |
in the general | 44 |
are able to | 44 |
therapy in patients | 44 |
a significant reduction | 44 |
most common cause | 44 |
characteristics of the | 44 |
patients who developed | 44 |
we present a | 44 |
immune repertoire classification | 44 |
with hematological malignancies | 44 |
diagnosis and management | 44 |
a major cause | 44 |
diagnosis and treatment | 44 |
time from diagnosis | 44 |
and did not | 44 |
patients undergoing allogeneic | 44 |
toxic shock syndrome | 44 |
may not be | 44 |
active antiretroviral therapy | 44 |
used for the | 44 |
of invasive fungal | 44 |
high risk for | 44 |
of infection in | 44 |
in t cells | 44 |
year cumulative incidence | 44 |
had to be | 44 |
role of the | 44 |
from healthy donors | 44 |
followed by autologous | 44 |
is involved in | 44 |
and has been | 44 |
primary graft failure | 43 |
needs to be | 43 |
of the donor | 43 |
with the use | 43 |
days after transplantation | 43 |
these results suggest | 43 |
all of the | 43 |
and should be | 43 |
in the number | 43 |
disease free survival | 43 |
in the liver | 43 |
for these patients | 43 |
large number of | 43 |
renal transplant patients | 43 |
the median duration | 43 |
unrelated cord blood | 43 |
independently associated with | 43 |
data show that | 43 |
incidence of grade | 43 |
guidelines for the | 43 |
peripheral blood in | 43 |
who underwent allogeneic | 43 |
modern hopfield networks | 43 |
of graft failure | 43 |
from unrelated donors | 43 |
with the development | 43 |
for the management | 43 |
the patients had | 43 |
for children with | 43 |
invasive fungal infection | 43 |
we present the | 43 |
were isolated from | 43 |
of grade ii | 43 |
a cause of | 43 |
the most commonly | 43 |
total number of | 43 |
of mg kg | 43 |
in allogeneic hematopoietic | 43 |
were compared with | 43 |
prior to transplant | 43 |
and in patients | 43 |
is thought to | 43 |
stem cell mobilization | 43 |
inflammatory bowel disease | 43 |
in patients without | 42 |
be able to | 42 |
we were able | 42 |
in the future | 42 |
the dose of | 42 |
vg vd t | 42 |
chronic gvhd and | 42 |
during the study | 42 |
reduce the risk | 42 |
in the two | 42 |
acute respiratory distress | 42 |
for gvhd prophylaxis | 42 |
considered to be | 42 |
and graft survival | 42 |
in heart transplant | 42 |
of them were | 42 |
were analyzed by | 42 |
and months after | 42 |
or absence of | 42 |
males and females | 42 |
infection in a | 42 |
and cord blood | 42 |
the mechanism of | 42 |
proved to be | 42 |
in the transplant | 42 |
were significantly higher | 42 |
and outcomes of | 42 |
and cd cd | 42 |
found that the | 42 |
of death were | 42 |
of overall survival | 42 |
we sought to | 42 |
time of the | 42 |
were no significant | 42 |
the cd cd | 42 |
was well tolerated | 42 |
prior to transplantation | 41 |
car t cells | 41 |
well as in | 41 |
engraftment was days | 41 |
occurred in of | 41 |
severe chronic gvhd | 41 |
in hsct recipients | 41 |
of our patients | 41 |
for detection of | 41 |
the current study | 41 |
use of the | 41 |
and the other | 41 |
melphalan mg m | 41 |
compared to controls | 41 |
significant difference between | 41 |
responsible for the | 41 |
have been used | 41 |
was performed to | 41 |
bone marrow in | 41 |
two patients with | 41 |
were positive for | 41 |
patients with mm | 41 |
case of a | 41 |
treatment option for | 41 |
for more than | 41 |
in this cohort | 41 |
out of the | 41 |
of the skin | 41 |
cmv reactivation was | 41 |
the start of | 41 |
patients did not | 41 |
secondary graft failure | 41 |
the respiratory tract | 41 |
in the second | 41 |
can be considered | 41 |
results indicate that | 41 |
conditioning regimen for | 41 |
reported in the | 41 |
led to the | 41 |
of breast milk | 41 |
kg kg tag | 41 |
infection and disease | 41 |
with acute myeloid | 41 |
patients at risk | 41 |
months after transplant | 41 |
prevention and treatment | 41 |
is able to | 40 |
varicella zoster virus | 40 |
we hypothesize that | 40 |
approved by the | 40 |
hla class i | 40 |
response to the | 40 |
at the university | 40 |
may result in | 40 |
mechanism of action | 40 |
the relationship between | 40 |
and for the | 40 |
purpose of this | 40 |
and of patients | 40 |
did not show | 40 |
defined as the | 40 |
diffuse large b | 40 |
is required for | 40 |
no statistically significant | 40 |
in our institution | 40 |
in the graft | 40 |
patients diagnosed with | 40 |
for up to | 40 |
in our experience | 40 |
and use of | 40 |
sickle cell disease | 40 |
the emergence of | 40 |
the association between | 40 |
treated with a | 40 |
at this time | 40 |
patients who have | 40 |
in most cases | 40 |
children and adults | 40 |
group and in | 40 |
overall survival and | 40 |
was not significantly | 40 |
the intensive care | 40 |
are involved in | 40 |
led to a | 40 |
via breast milk | 40 |
for the patients | 40 |
on the outcome | 40 |
remains to be | 40 |
presence of a | 40 |
of the ebmt | 40 |
no effect on | 40 |
a matched unrelated | 40 |
of solid organ | 40 |
our results suggest | 40 |
infection in patients | 40 |
and of the | 40 |
of the t | 39 |
related or unrelated | 39 |
the last years | 39 |
adoptive transfer of | 39 |
of the literature | 39 |
we report on | 39 |
in the peripheral | 39 |
a lack of | 39 |
and function of | 39 |
was to assess | 39 |
in the donor | 39 |
and risk factors | 39 |
of cytomegalovirus infection | 39 |
delta t cells | 39 |
the patient had | 39 |
associated with high | 39 |
higher in patients | 39 |
even in the | 39 |
incidence of chronic | 39 |
patients with an | 39 |
these data suggest | 39 |
in the lung | 39 |
t cell development | 39 |
was not associated | 39 |
time of transplantation | 39 |
patient with a | 39 |
cyclophosphamide mg kg | 39 |
their ability to | 39 |
specific t cell | 39 |
of severe acute | 39 |
of acute rejection | 39 |
were the most | 39 |
be effective in | 39 |
in this retrospective | 39 |
immunoglobulin replacement therapy | 39 |
member of the | 39 |
be used for | 39 |
with bone marrow | 39 |
it may be | 39 |
platelet engraftment was | 39 |
was measured by | 39 |
and it is | 39 |
chronic gvhd were | 39 |
lead to a | 39 |
in the icu | 39 |
hsct in our | 39 |
were no differences | 39 |
cd cells in | 38 |
should not be | 38 |
for the presence | 38 |
mhc class ii | 38 |
be related to | 38 |
study of the | 38 |
results in a | 38 |
we demonstrated that | 38 |
occurred in the | 38 |
regimen consisted of | 38 |
of death in | 38 |
at a single | 38 |
gvhd grade ii | 38 |
may have a | 38 |
the group of | 38 |
than in the | 38 |
to be an | 38 |
cd cd t | 38 |
donor lymphocyte infusion | 38 |
a mean of | 38 |
of the same | 38 |
were performed using | 38 |
impact of the | 38 |
was based on | 38 |
analyses were performed | 38 |
of patients was | 38 |
who underwent hsct | 38 |
as a consequence | 38 |
patients had received | 38 |
no differences in | 38 |
seem to be | 38 |
days after hsct | 38 |
performed a retrospective | 38 |
and b cell | 38 |
and the risk | 38 |
development of a | 38 |
was peripheral blood | 38 |
risk factors and | 38 |
with cmv reactivation | 38 |
be used in | 38 |
who underwent allo | 38 |
class i molecules | 38 |
at months after | 38 |
overall survival of | 38 |
majority of the | 38 |
we describe a | 38 |
from a matched | 38 |
we compared the | 38 |
was the only | 37 |
was not statistically | 37 |
due to its | 37 |
patients were enrolled | 37 |
in the high | 37 |
relapsed or refractory | 37 |
the potential to | 37 |
respiratory tract infection | 37 |
caused by a | 37 |
no difference between | 37 |
high dose chemotherapy | 37 |
difference between the | 37 |
was evaluated by | 37 |
and the presence | 37 |
in high risk | 37 |
the formation of | 37 |
differences between the | 37 |
were excluded from | 37 |
obtained from the | 37 |
conditioning regimen and | 37 |
the risk factors | 37 |
the activity of | 37 |
result in a | 37 |
increased expression of | 37 |
sinusoidal obstruction syndrome | 37 |
considered as a | 37 |
the appearance of | 37 |
human herpes virus | 37 |
conditioning regimens were | 37 |
was a significant | 37 |
results demonstrate that | 37 |
were determined by | 37 |
the control of | 37 |
with evidence of | 37 |
as high as | 37 |
blood samples were | 37 |
after solid organ | 37 |
was similar in | 37 |
t cells that | 37 |
one patient developed | 37 |
were enrolled in | 37 |
is essential for | 37 |
infection has been | 37 |
this may be | 37 |
first year after | 37 |
effector t cells | 37 |
of invasive aspergillosis | 37 |
on the use | 37 |
viral load in | 37 |
nature of the | 37 |
a year old | 37 |
patients with cd | 37 |
in patients treated | 37 |
we showed that | 37 |
at increased risk | 37 |
mesenchymal stem cells | 37 |
in the management | 37 |
presence or absence | 36 |
chronic graft versus | 36 |
significantly higher than | 36 |
cytomegalovirus disease in | 36 |
was analyzed by | 36 |
a myeloablative conditioning | 36 |
of allogeneic stem | 36 |
overall response rate | 36 |
peripheral blood of | 36 |
donor lymphocyte infusions | 36 |
and fungal infections | 36 |
after kidney transplantation | 36 |
in lung transplantation | 36 |
we studied the | 36 |
a series of | 36 |
in neutropenic patients | 36 |
a role for | 36 |
be explained by | 36 |
are known to | 36 |
is safe and | 36 |
the response to | 36 |
transplant recipients and | 36 |
a reduced intensity | 36 |
of b cell | 36 |
of the infection | 36 |
in line with | 36 |
was shown to | 36 |
among the patients | 36 |
of pts with | 36 |
in two patients | 36 |
intensity conditioning regimen | 36 |
important cause of | 36 |
can result in | 36 |
the patients received | 36 |
of the transplant | 36 |
to be more | 36 |
red blood cells | 36 |
bei patienten mit | 36 |
were compared to | 36 |
of gvhd and | 36 |
as early as | 36 |
and the patient | 36 |
it should be | 36 |
in the pre | 36 |
cd cd cells | 36 |
all patients engrafted | 36 |
mutation in the | 36 |
and mortality after | 36 |
stem cell transplants | 36 |
stem cells in | 36 |
the study period | 36 |
innate and adaptive | 36 |
described in the | 36 |
may be used | 36 |
have to be | 36 |
findings suggest that | 36 |
than that of | 36 |
been used in | 36 |
to determine if | 36 |
at least months | 36 |
of human immunodeficiency | 35 |
patients who did | 35 |
as shown in | 35 |
was supported by | 35 |
of infectious diseases | 35 |
for blood and | 35 |
appear to be | 35 |
the range of | 35 |
in the regulation | 35 |
were measured by | 35 |
mg kg on | 35 |
a mouse model | 35 |
the entire cohort | 35 |
resistant staphylococcus aureus | 35 |
years after transplantation | 35 |
bal fluid specimens | 35 |
aim was to | 35 |
which may be | 35 |
of patients undergoing | 35 |
performed in patients | 35 |
combined immune deficiency | 35 |
cells from the | 35 |
there have been | 35 |
in kidney transplant | 35 |
overall survival in | 35 |
between patients with | 35 |
age at hsct | 35 |
cytotoxic t cells | 35 |
patients transplanted from | 35 |
the cell surface | 35 |
at one year | 35 |
results show that | 35 |
a statistically significant | 35 |
the patients was | 35 |
a subset of | 35 |
lower in the | 35 |
of hepatitis c | 35 |
that have been | 35 |
derived from the | 35 |
it can be | 35 |
immune response to | 35 |
which can be | 35 |
main cause of | 35 |
systemic lupus erythematosus | 35 |
moderate to severe | 35 |
in the multivariate | 35 |
in critically ill | 35 |
activated t cells | 35 |
were transplanted from | 35 |
conditioning regimen consisted | 34 |
disease caused by | 34 |
liposomal amphotericin b | 34 |
the site of | 34 |
different time points | 34 |
abstract already published | 34 |
mouse model of | 34 |
cytotoxic t lymphocytes | 34 |
in the current | 34 |
cmv reactivation and | 34 |
could be used | 34 |
in the pediatric | 34 |
risk of gvhd | 34 |
or in combination | 34 |
of at least | 34 |
to test the | 34 |
days after the | 34 |
in patients at | 34 |
disease in the | 34 |
in a multivariate | 34 |
failure to thrive | 34 |
b and t | 34 |
similar to that | 34 |
single center experience | 34 |
heart and lung | 34 |
cmv infection and | 34 |
for disease control | 34 |
the availability of | 34 |
course of the | 34 |
presence of the | 34 |
patients with hematologic | 34 |
has been suggested | 34 |
adverse events were | 34 |
mg kg d | 34 |
age at diagnosis | 34 |
patients transplanted with | 34 |
time of days | 34 |
may be considered | 34 |
to increase the | 34 |
a higher risk | 34 |
efficacy of the | 34 |
and at the | 34 |
hsct in patients | 34 |
the multivariate analysis | 34 |
of the pts | 34 |
a panel of | 34 |
do not have | 34 |
free survival was | 34 |
the levels of | 34 |
performed in the | 34 |
of the cmv | 34 |
of the illness | 34 |
patient and graft | 34 |
in a dose | 34 |
is a well | 34 |
and is associated | 33 |
cells and the | 33 |
with an average | 33 |
in group a | 33 |
children and adolescents | 33 |
patients with the | 33 |
reactivation of latent | 33 |
significant differences between | 33 |
the main cause | 33 |
which is a | 33 |
the diagnosis and | 33 |
primary immune deficiency | 33 |
of the clinical | 33 |
infections of the | 33 |
national institute of | 33 |
was a trend | 33 |
significant morbidity and | 33 |
were reported in | 33 |
of relapse was | 33 |
the disease is | 33 |
caused by the | 33 |
risk of cmv | 33 |
of the present | 33 |
in both the | 33 |
successfully treated with | 33 |
we retrospectively reviewed | 33 |
on behalf of | 33 |
patients in cr | 33 |
significant reduction in | 33 |
a matched sibling | 33 |
x cd cells | 33 |
these results demonstrate | 33 |
is defined as | 33 |
and response to | 33 |
the progression of | 33 |
as a cause | 33 |
and had a | 33 |
a matched related | 33 |
used to treat | 33 |
been identified in | 33 |
incidence of agvhd | 33 |
b and c | 33 |
the infectious diseases | 33 |
length of stay | 33 |
should be given | 33 |
decrease in the | 33 |
will be presented | 33 |
in bal fluid | 33 |
similar to those | 33 |
history of recurrent | 33 |
there is an | 33 |
is due to | 33 |
statistically significant difference | 33 |
were divided into | 33 |
event free survival | 33 |
often associated with | 33 |
of patients received | 33 |
of the following | 33 |
factors such as | 33 |
similar to the | 33 |
common in the | 33 |
a member of | 33 |
production of il | 33 |
prospective study of | 33 |
we report our | 33 |
over the last | 33 |
of them had | 33 |
treatment of the | 32 |
according to our | 32 |
from bone marrow | 32 |
a safe and | 32 |
seen in patients | 32 |
in accordance with | 32 |
lower incidence of | 32 |
treatment of cmv | 32 |
the goal of | 32 |
with a low | 32 |
the result of | 32 |
were identified as | 32 |
been observed in | 32 |
or in the | 32 |
and to the | 32 |
was significantly associated | 32 |
in the past | 32 |
correlated with the | 32 |
should be performed | 32 |
as opposed to | 32 |
more frequent in | 32 |
of regulatory t | 32 |
severe aplastic anemia | 32 |
who had received | 32 |
in the recipient | 32 |
overall survival at | 32 |
was to investigate | 32 |
respiratory viral infections | 32 |
can be seen | 32 |
a consequence of | 32 |
is a frequent | 32 |
leading cause of | 32 |
showed a significant | 32 |
alloreactive t cells | 32 |
to elucidate the | 32 |
cells and cd | 32 |
patients undergoing hsct | 32 |
we examined the | 32 |
and development of | 32 |
these patients were | 32 |
with increased risk | 32 |
to those of | 32 |
we have shown | 32 |
clinical manifestations of | 32 |
mg twice daily | 32 |
compared with those | 32 |
are at risk | 32 |
transplanted in cr | 32 |
risk of graft | 32 |
the contribution of | 32 |
the efficacy and | 32 |
treatment of patients | 32 |
similar in both | 32 |
cells can be | 32 |
isolated from the | 32 |
due to their | 32 |
compared to non | 32 |
of the lung | 32 |
data with implanted | 32 |
of consecutive patients | 32 |
in this case | 32 |
is not clear | 32 |
virus infections in | 32 |
is necessary to | 32 |
of the graft | 32 |
the likelihood of | 32 |
characterized by a | 32 |
patients with refractory | 32 |
developed acute gvhd | 32 |
of these infections | 32 |
related mortality was | 32 |
correlation between the | 31 |
in the bone | 31 |
acute myeloid leukaemia | 31 |
cells of the | 31 |
or bone marrow | 31 |
could be a | 31 |
in hsct patients | 31 |
a trend for | 31 |
for the detection | 31 |
t cells by | 31 |
is to evaluate | 31 |
a high risk | 31 |
an increase of | 31 |
in any of | 31 |
significantly different between | 31 |
to healthy controls | 31 |
with cmv infection | 31 |
patients affected by | 31 |
treatment related mortality | 31 |
d and d | 31 |
the application of | 31 |
based on a | 31 |
for the entire | 31 |
transplantation in the | 31 |
was to determine | 31 |
here we present | 31 |
by western blot | 31 |
survival in patients | 31 |
has been identified | 31 |
consistent with the | 31 |
is not a | 31 |
in conjunction with | 31 |
it is a | 31 |
graft failure and | 31 |
the most frequently | 31 |
the evaluation of | 31 |
shown in figure | 31 |
to confirm the | 31 |
all patients who | 31 |
a child with | 31 |
the early post | 31 |
in some patients | 31 |
a significant difference | 31 |
of choice for | 31 |
was to analyze | 31 |
in situ hybridization | 31 |
were tested for | 31 |
consecutive patients with | 31 |
differences were observed | 31 |
no conflict of | 31 |
with the exception | 31 |
of hepatitis b | 31 |
at the last | 31 |
more than months | 31 |
significant impact on | 31 |
is shown in | 31 |
were in cr | 31 |
may play a | 31 |
of cytomegalovirus disease | 31 |
outcomes of patients | 31 |
and type of | 31 |
analysis showed that | 31 |
as measured by | 31 |
response to treatment | 31 |
high level of | 31 |
we aim to | 31 |
next generation sequencing | 31 |
were defined as | 31 |
patients with mds | 31 |
an attempt to | 31 |
low incidence of | 31 |
for high risk | 31 |
present study was | 31 |
bacterial and fungal | 31 |
small number of | 31 |
the timing of | 31 |
an important cause | 31 |
should be used | 31 |
stem cells from | 30 |
months after the | 30 |
with primary immunodeficiency | 30 |
the presence or | 30 |
to be safe | 30 |
in all groups | 30 |
with implanted signals | 30 |
the median of | 30 |
cells in a | 30 |
school of medicine | 30 |
to of patients | 30 |
chronic myeloid leukemia | 30 |
this group of | 30 |
acquired immunodeficiency syndrome | 30 |
with acute gvhd | 30 |
in patients transplanted | 30 |
the diagnosis is | 30 |
hematopoietic cell transplant | 30 |
the nature of | 30 |
treatment for patients | 30 |
day and day | 30 |
the hypothesis that | 30 |
patients were diagnosed | 30 |
identification of the | 30 |
in a prospective | 30 |
and quality of | 30 |
be caused by | 30 |
in allogeneic stem | 30 |
majority of cases | 30 |
peripheral blood and | 30 |
after days of | 30 |
and lung transplantation | 30 |
been shown that | 30 |
also been reported | 30 |
of human herpesvirus | 30 |
the kinetics of | 30 |
conflicts of interest | 30 |
tomato leaf curl | 30 |
disease control and | 30 |
to examine the | 30 |
up to years | 30 |
without evidence of | 30 |
bone marrow cells | 30 |
were analyzed for | 30 |
cmv infection is | 30 |
primary immunodeficiency diseases | 30 |
and at years | 30 |
increase the risk | 30 |
be given to | 30 |
colony stimulating factor | 30 |
that patients with | 30 |
in the post | 30 |
percent of patients | 30 |
identified in the | 30 |
in vivo t | 30 |
cd t lymphocyte | 30 |
of cmv dna | 30 |
t cell subsets | 30 |
to the infant | 30 |
the last decade | 30 |
in human immunodeficiency | 30 |
chronic gvhd in | 30 |
our results show | 30 |
many of the | 30 |
determined by the | 30 |
the mean age | 30 |
has been observed | 30 |
with hematologic malignancies | 30 |
study was conducted | 30 |
demonstrated that the | 30 |
but it is | 30 |
the immunocompromised host | 30 |
cell dose was | 30 |
therapy in the | 30 |
used in patients | 30 |
were performed with | 30 |
the in vivo | 30 |
at different time | 30 |
was bone marrow | 30 |
the release of | 30 |
up of days | 30 |
patients were followed | 30 |
treatment of choice | 30 |
serve as a | 30 |
our study was | 30 |
use of a | 30 |
the innate immune | 30 |
have been developed | 30 |
no impact on | 30 |
is a highly | 30 |
the period of | 30 |
survival at years | 30 |
to understand the | 30 |
the intensity of | 30 |
wide range of | 30 |
or unrelated donor | 30 |
well as a | 30 |
revealed that the | 30 |
to define the | 30 |
progressive multifocal leukoencephalopathy | 30 |
within days after | 29 |
conducted a retrospective | 29 |
immunodeficiency virus type | 29 |
in a significant | 29 |
were in complete | 29 |
of cmv pneumonia | 29 |
of the total | 29 |
patients compared to | 29 |
patients with cancer | 29 |
a crucial role | 29 |
of these cells | 29 |
the initiation of | 29 |
university medical center | 29 |
of infection and | 29 |
with median age | 29 |
for a median | 29 |
be treated with | 29 |
engraftment was achieved | 29 |
the mechanisms of | 29 |
a multivariate analysis | 29 |
cd cells from | 29 |
reduction of the | 29 |
patients receiving a | 29 |
ranging from to | 29 |
t cell function | 29 |
can be a | 29 |
significant reduction of | 29 |
that may be | 29 |
control of the | 29 |
of cmv in | 29 |
as an alternative | 29 |
the study is | 29 |
of inkt cells | 29 |
leads to a | 29 |
with a mean | 29 |
lead to the | 29 |
cell transplantation from | 29 |
national institutes of | 29 |
associated with lower | 29 |
the cells were | 29 |
the group with | 29 |
were conditioned with | 29 |
factors for the | 29 |
based on these | 29 |
was in the | 29 |
as soon as | 29 |
were more likely | 29 |
there has been | 29 |
of the cells | 29 |
had a significantly | 29 |
statistical analysis was | 29 |
the patients in | 29 |
first complete remission | 29 |
and in vitro | 29 |
patients with pid | 29 |
may be associated | 29 |
is a potentially | 29 |
the value of | 29 |
in the immune | 29 |
part of a | 29 |
of patients treated | 29 |
the performance of | 29 |
supported by the | 29 |
with a significant | 29 |
were not significantly | 29 |
higher rate of | 29 |
we describe the | 29 |
cmv reactivation in | 29 |
received myeloablative conditioning | 29 |
in the atg | 29 |
after hsct and | 29 |
regimen was myeloablative | 29 |
the exception of | 29 |
cell activation and | 29 |
recipients of allogeneic | 29 |
and months post | 29 |
of acute graft | 29 |
in the non | 29 |
median dose of | 29 |
is likely to | 29 |
of relapse and | 29 |
alone or in | 29 |
and the development | 29 |
from day to | 29 |
and grade iii | 29 |
to play a | 29 |
which has been | 29 |
were identified in | 29 |
in the elderly | 28 |
developed chronic gvhd | 28 |
was given to | 28 |
is a risk | 28 |
t cells is | 28 |
is a significant | 28 |
cd cd foxp | 28 |
cell proliferation and | 28 |
and days after | 28 |
vd t cells | 28 |
mortality in the | 28 |
in the spleen | 28 |
centers for disease | 28 |
in multiple myeloma | 28 |
in the hsct | 28 |
primary endpoint was | 28 |
risk factors of | 28 |
patients with non | 28 |
on day was | 28 |
between and were | 28 |
enrolled in the | 28 |
evaluate the impact | 28 |
a high rate | 28 |
might be a | 28 |
did not respond | 28 |
of patients at | 28 |
and a median | 28 |
be seen in | 28 |
a reduction of | 28 |
gvhd occurred in | 28 |
patient had a | 28 |
had no effect | 28 |
was myeloablative in | 28 |
year after hsct | 28 |
time of diagnosis | 28 |
age of patients | 28 |
stem cells were | 28 |
b cell lymphoma | 28 |
after weeks of | 28 |
signs and symptoms | 28 |
an effective treatment | 28 |
phase of the | 28 |
was negative for | 28 |
of the il | 28 |
up to months | 28 |
infection can be | 28 |
older than years | 28 |
to explore the | 28 |
patients from the | 28 |
institutes of health | 28 |
data not shown | 28 |
in relation to | 28 |
reported to the | 28 |
has the potential | 28 |
were similar in | 28 |
be responsible for | 28 |
allogeneic hsct in | 28 |
and the number | 28 |
the patient and | 28 |
pfs and os | 28 |
working party of | 28 |
to months after | 28 |
patients with all | 28 |
immunodeficiency virus infection | 28 |
kg body weight | 28 |
in clinical trials | 28 |
of donor t | 28 |
conditioning regimen with | 28 |
one of them | 28 |
samples from patients | 28 |
in aids patients | 28 |
the rest of | 28 |
of patients receiving | 28 |
of the major | 28 |
consecutive patients who | 28 |
to describe the | 28 |
of age and | 28 |
in liver transplant | 28 |
a large number | 28 |
increased in the | 28 |
can be detected | 28 |
data were collected | 28 |
in the cd | 28 |
transmission of hiv | 28 |
which could be | 28 |
and disease free | 28 |
with relapsed refractory | 28 |
of allogeneic hsct | 28 |
regardless of the | 28 |
the donor was | 28 |
higher levels of | 28 |
first months after | 28 |
the loss of | 28 |
associated with acute | 28 |
world health organization | 28 |
was identified in | 28 |
found in patients | 28 |
of adult patients | 28 |
we used a | 28 |
was obtained from | 27 |
control and prevention | 27 |
patients with cgd | 27 |
a significant proportion | 27 |
ranged from to | 27 |
well tolerated and | 27 |
in partial remission | 27 |
prevention of cytomegalovirus | 27 |
therapy for patients | 27 |
increased incidence of | 27 |
in up to | 27 |
may be an | 27 |
a significant decrease | 27 |
for acute myeloid | 27 |
who received an | 27 |
the feasibility of | 27 |
pts received a | 27 |
in the mother | 27 |
a key role | 27 |
graft failure was | 27 |
complete donor chimerism | 27 |
and activation of | 27 |
large cohort of | 27 |
mg kg iv | 27 |
clinical features of | 27 |
significant proportion of | 27 |
with at least | 27 |
is feasible and | 27 |
did not influence | 27 |
party of the | 27 |
to develop a | 27 |
median time for | 27 |
year after transplantation | 27 |
also associated with | 27 |
one case of | 27 |
in the urine | 27 |
of them received | 27 |
during the period | 27 |
was reported in | 27 |
associated with significant | 27 |
t cell depleted | 27 |
male and female | 27 |
in vivo and | 27 |
of viral infection | 27 |
a range of | 27 |
in group b | 27 |
cd b cells | 27 |
the infusion of | 27 |
detected in patients | 27 |
none of these | 27 |
the choice of | 27 |
of renal function | 27 |
hemorrhagic cystitis in | 27 |
did not affect | 27 |
with chronic gvhd | 27 |
first year of | 27 |
was added to | 27 |
the characteristics of | 27 |
to neutrophil engraftment | 27 |
of immune suppression | 27 |
patients transplanted in | 27 |
and number of | 27 |
after allogeneic sct | 27 |
mg m d | 27 |
data demonstrate that | 27 |
two of them | 27 |
early in the | 27 |
the first years | 27 |
the immune status | 27 |
in the thymus | 27 |
a high mortality | 27 |
serum levels of | 27 |
comparison of the | 27 |
gvhd was observed | 27 |
from matched unrelated | 27 |
with the highest | 27 |
be found in | 27 |
it is also | 27 |
medical records of | 27 |
iga and igm | 27 |
to characterize the | 27 |
viral infections are | 27 |
we developed a | 27 |
t cell counts | 27 |
the liver and | 27 |
and lack of | 27 |
source was peripheral | 27 |
t cell lymphopenia | 27 |
area under the | 27 |
for hematologic malignancies | 27 |
cell transplantation with | 27 |
at day post | 27 |
increased susceptibility to | 27 |
in transplant patients | 27 |
haploidentical hematopoietic stem | 27 |
in all the | 27 |
univariate and multivariate | 27 |
groups of patients | 27 |
were performed at | 27 |
that of the | 27 |
mainly due to | 27 |
and platelet recovery | 27 |
for pts with | 27 |
considered in the | 27 |
median time between | 27 |
at any time | 27 |
of primary immunodeficiency | 27 |
bone marrow biopsy | 27 |
in the remaining | 27 |
a critical role | 27 |
of the european | 27 |
high rates of | 27 |
with active disease | 26 |
was referred to | 26 |
absolute neutrophil count | 26 |
un trasplante de | 26 |
received a myeloablative | 26 |
an incidence of | 26 |
during this period | 26 |
may be required | 26 |
in first complete | 26 |
of patients are | 26 |
as stem cell | 26 |
gvhd prophylaxis in | 26 |
did not reach | 26 |
with high dose | 26 |
specific cytotoxic t | 26 |
on the day | 26 |
january and december | 26 |
all but one | 26 |
was due to | 26 |
curative option for | 26 |
is a curative | 26 |
compared to a | 26 |
based gvhd prophylaxis | 26 |
age at transplantation | 26 |
patients were alive | 26 |
invasive pulmonary aspergillosis | 26 |
complication of allogeneic | 26 |
the distribution of | 26 |
likely to have | 26 |
de un trasplante | 26 |
higher than that | 26 |
no signs of | 26 |
yellow fever virus | 26 |
innate immune system | 26 |
human immunodefi ciency | 26 |
to neutrophil and | 26 |
of infection with | 26 |
a single dose | 26 |
essential for the | 26 |
compared with patients | 26 |
in our patient | 26 |
treatment of acute | 26 |
to decrease the | 26 |
in the table | 26 |
only curative treatment | 26 |
mg kg for | 26 |
in those patients | 26 |
insights into the | 26 |
diagnosis of cmv | 26 |
regimen consisting of | 26 |
less likely to | 26 |
between day and | 26 |
stem cells transplantation | 26 |
is mediated by | 26 |
mg m on | 26 |
the cases of | 26 |
reduce the incidence | 26 |
the extent of | 26 |
the recovery of | 26 |
to respond to | 26 |
significantly increased in | 26 |
in the t | 26 |
in spite of | 26 |
is needed to | 26 |
surface expression of | 26 |
are required to | 26 |
compared to control | 26 |
were detected by | 26 |
regulation of the | 26 |
test was used | 26 |
poor graft function | 26 |
or unrelated donors | 26 |
compared to that | 26 |
in these cases | 26 |
can be found | 26 |
autologous peripheral blood | 26 |
acute gvhd in | 26 |
the ci of | 26 |
in the induction | 26 |
at day after | 26 |
infections caused by | 26 |
et al reported | 26 |
who presented with | 26 |
retrospective chart review | 26 |
natural history of | 26 |
were assessed by | 26 |
two patients had | 26 |
of the innate | 26 |
a wide range | 26 |
and viral infections | 26 |
the transcription factor | 26 |
and patients were | 26 |
and t cells | 26 |
of the human | 26 |
an analysis of | 26 |
and review of | 26 |
activity of the | 26 |
in the skin | 26 |
independent risk factors | 26 |
one year after | 26 |
reduction of immunosuppression | 26 |
using flow cytometry | 26 |
of immune reconstitution | 26 |
function of the | 26 |
old male with | 26 |
with aml in | 26 |
was to compare | 26 |
low levels of | 26 |
and there was | 26 |
for use in | 26 |
especially in the | 26 |
report of the | 26 |
we have developed | 26 |
time of hsct | 26 |
viral infections and | 26 |
who received hsct | 26 |
in stem cell | 26 |
plays an important | 26 |
the ratio of | 26 |
of viral load | 26 |
were transplanted with | 26 |
b and nk | 26 |
emerson et al | 26 |
in aml patients | 26 |
cd cells was | 26 |
cd cd ra | 26 |
en receptores de | 26 |
os and dfs | 26 |
immune response in | 26 |
el tratamiento de | 26 |
survival in the | 26 |
the establishment of | 25 |
median cd cell | 25 |
median overall survival | 25 |
at months was | 25 |
indicate that the | 25 |
used to assess | 25 |
did not develop | 25 |
between and at | 25 |
chez les patients | 25 |
the form of | 25 |
be an effective | 25 |
undergoing allogeneic hematopoietic | 25 |
results of this | 25 |
of immunosuppressive therapy | 25 |
received peripheral blood | 25 |
infected patients with | 25 |
survival rate was | 25 |
cord blood in | 25 |
of the underlying | 25 |
incidence of gvhd | 25 |
the transplant recipient | 25 |
in the incidence | 25 |
influenza a virus | 25 |
is limited by | 25 |
in our centre | 25 |
early diagnosis and | 25 |
conditioning regimen in | 25 |
plasma levels of | 25 |
and patient survival | 25 |
not differ between | 25 |
t cells for | 25 |
features of the | 25 |
was complicated by | 25 |
the potential of | 25 |
allogeneic hsct recipients | 25 |
transplant lymphoproliferative disorder | 25 |
of t and | 25 |
cells in vitro | 25 |
mortality after allogeneic | 25 |
lung transplant patients | 25 |
to the treatment | 25 |
significant differences were | 25 |
the university hospital | 25 |
of the current | 25 |
due to an | 25 |
primary and secondary | 25 |
an average of | 25 |
must be considered | 25 |
be safe and | 25 |
hsct from a | 25 |
nk cells in | 25 |
the underlying disease | 25 |
had at least | 25 |
b cells were | 25 |
as a potential | 25 |
the last follow | 25 |
to detect the | 25 |
nk cells and | 25 |
most of these | 25 |
aim of our | 25 |
at and months | 25 |
natural killer cells | 25 |
cmv viral load | 25 |
first days after | 25 |
cells have been | 25 |
data are available | 25 |
significant difference was | 25 |
to this end | 25 |
sensitivity and specificity | 25 |
more than days | 25 |
of which were | 25 |
high prevalence of | 25 |
leading to a | 25 |
in subjects with | 25 |
caused by mutations | 25 |
is also a | 25 |
and total body | 25 |
goal of this | 25 |
all patients in | 25 |
a minimum of | 25 |
results showed that | 25 |
the increase in | 25 |
for diagnosis of | 25 |
patient died of | 25 |
have a high | 25 |
time to platelet | 25 |
group compared to | 25 |
likely due to | 25 |
der nachweis von | 25 |
activated b cells | 25 |
have been performed | 25 |
were not different | 25 |
by cd t | 25 |
to identify patients | 25 |
cytokine release syndrome | 25 |
and autologous stem | 25 |
patients had an | 25 |
our understanding of | 25 |
to of the | 25 |
received an allogeneic | 25 |
nothing to disclose | 25 |
nk cells were | 25 |
and reduced intensity | 25 |
relapse or progression | 25 |
transplant patients with | 25 |
the development and | 25 |
hla identical sibling | 25 |
cells were isolated | 25 |
and high risk | 25 |
la incidencia de | 25 |
associated with better | 25 |
mortality in patients | 25 |
for patients in | 25 |
who do not | 25 |
breast milk is | 25 |
at diagnosis was | 25 |
the same donor | 25 |
added to the | 25 |
it is unclear | 25 |
most commonly used | 25 |
the differential diagnosis | 25 |
months post transplant | 25 |
the cost of | 25 |
urinary tract infections | 25 |
compared to in | 25 |
renal transplant recipient | 25 |
to those with | 25 |
leads to the | 25 |
on the first | 25 |
patients with and | 25 |
peripheral blood was | 25 |
the cd t | 25 |
as determined by | 25 |
at mg kg | 25 |
flow cytometric analysis | 25 |
and hematopoietic stem | 25 |
is a safe | 25 |
in elderly patients | 25 |
of the anti | 25 |
were stimulated with | 25 |
of this approach | 25 |
were significantly lower | 25 |
of opportunistic infections | 25 |
the prognosis of | 25 |
pneumocystis jirovecii pneumonia | 25 |
transmission of hepatitis | 25 |
mild to moderate | 25 |
especially in patients | 25 |
who had undergone | 25 |
who had a | 25 |
identical sibling donor | 25 |
cord blood transplant | 25 |
not been reported | 25 |
through breast milk | 25 |
to establish the | 25 |
patients after allogeneic | 24 |
to the hospital | 24 |
disease due to | 24 |
in a small | 24 |
infants and children | 24 |
foxp t cells | 24 |
in of them | 24 |
in severe cases | 24 |
high mortality rate | 24 |
was performed at | 24 |
in the period | 24 |
by the use | 24 |
during the course | 24 |
patients died of | 24 |
of treatment with | 24 |
is related to | 24 |
in a mouse | 24 |
referred to as | 24 |
transplant recipients are | 24 |
parvovirus b infection | 24 |
gvhd of the | 24 |
recipients in the | 24 |
these data indicate | 24 |
cd t lymphocytes | 24 |
between both groups | 24 |
was not different | 24 |
the natural history | 24 |
after initiation of | 24 |
suggesting that the | 24 |
incidence and severity | 24 |
in organ transplant | 24 |
in renal transplantation | 24 |
was admitted to | 24 |
for acute leukemia | 24 |
mobilized peripheral blood | 24 |
it is possible | 24 |
and treated with | 24 |
previous studies have | 24 |
between and in | 24 |
be considered for | 24 |
is seen in | 24 |
cmv and ebv | 24 |
acute gvhd of | 24 |
contrast to the | 24 |
associated with severe | 24 |
and could be | 24 |
at hsct was | 24 |
to control the | 24 |
the incidences of | 24 |
transplantation in children | 24 |
infection in children | 24 |
disease has been | 24 |
mg kg and | 24 |
followed by the | 24 |
i and ii | 24 |
both cd and | 24 |
in the field | 24 |
during the last | 24 |
of more than | 24 |
cells as well | 24 |
and treatment with | 24 |
time of months | 24 |
the total number | 24 |
to the ebmt | 24 |
to obtain a | 24 |
may be seen | 24 |
in an infant | 24 |
the advent of | 24 |
and associated with | 24 |
year os and | 24 |
the etiology of | 24 |
the gi tract | 24 |
is not well | 24 |
after allogeneic bone | 24 |
in the late | 24 |
diseases such as | 24 |
detection of cmv | 24 |
these patients are | 24 |
in vitro studies | 24 |
had a significant | 24 |
of bk virus | 24 |
leading to the | 24 |
its role in | 24 |
mean age at | 24 |
has resulted in | 24 |
of the main | 24 |
agents such as | 24 |
are present in | 24 |
could lead to | 24 |
one of these | 24 |
of bacterial infections | 24 |
subset of patients | 24 |
as shown by | 24 |
a significant risk | 24 |
are presented in | 24 |
cumulative incidences of | 24 |
society of america | 24 |